RAS mutations are frequent in FAB type M4 and M5 of acute myeloid leukemia, and related to late relapse: A study of the japanese childhood AML cooperative study group

International Journal of Hematology

Volumn 95, Issue 5, 2012, Pages 509-515

  Sano, Hirozumi ^a   Shimada, Akira ^a   Taki, Tomohiko ^b   Murata, Chisato ^a   Park, Myoung Ja ^a   Sotomatsu, Manabu ^a   Tabuchi, Ken ^c   Tawa, Akio ^d   Kobayashi, Ryoji ^e   Horibe, Keizo ^f   Tsuchida, Masahiro ^g   Hanada, Ryoji ^h   Tsukimoto, Ichiro ⁱ   Hayashi, Yasuhide ^a  

^a Gunma Children's Medical Center   (Japan)

^b KYOTO PREFECTURAL UNIVERSITY OF MEDICINE   (Japan)

^c KANAGAWA CHILDREN'S MEDICAL CENTER   (Japan)

^d OSAKA NATIONAL HOSPITAL   (Japan)

^e SAPPORO HOKUYU HOSPITAL   (Japan)

^f NATIONAL HOSPITAL ORGANIZATION NAGOYA MEDICAL CENTER   (Japan)

^g Ibaraki Children's Hospital   (Japan)

^h SAITAMA CHILDREN'S MEDICAL CENTER   (Japan)

ⁱ TOHO UNIVERSITY SCHOOL OF MEDICINE   (Japan)

Author keywords

Acute myeloid leukemia; FAB; Late relapse; Prognosis; RAS

Indexed keywords

ACUTE GRANULOCYTIC LEUKEMIA; ADOLESCENT; ARTICLE; CHILD; CYTOGENETICS; DISEASE FREE SURVIVAL; FEMALE; GENE MUTATION; HUMAN; INFANT; LEUKEMIA RELAPSE; LEUKEMOGENESIS; MAJOR CLINICAL STUDY; MALE; NEWBORN; ONCOGENE K RAS; ONCOGENE N RAS; ONCOGENE RAS; OVERALL SURVIVAL;

ADOLESCENT; ASIAN CONTINENTAL ANCESTRY GROUP; CHILD; CHILD, PRESCHOOL; COHORT STUDIES; CYTOGENETIC ANALYSIS; FEMALE; HUMANS; INFANT; LEUKEMIA, MYELOID, ACUTE; MALE; MUTATION; PROGNOSIS; PROTO-ONCOGENE PROTEINS; PROTO-ONCOGENE PROTEINS P21(RAS); RAS PROTEINS; RECURRENCE;

EID: 84862864582     PISSN: 09255710     EISSN: 18653774     Source Type: Journal    
DOI: 10.1007/s12185-012-1033-x     Document Type: Article

References (22)

1. Gibson BE, Wheatley K, Hann IM, Stevens RF, Webb D, Hills RK, et al. Treatment strategy and long-term results in paediatric patients treated in consecutive UK AML trials. Leukemia. 2005;19:2130-8. (Pubitemid 41741605)
2. Lie SO, Abrahamsson J, Clausen N, Forestier E, Hasle H, Hovi L, et al. Long term results in children with AML: NOPHO-AML Study Group-report of three consecutive trials. Leukemia. 2005;19:2090-100. (Pubitemid 41741601)
3. Creutzig U, Zimmermann M, Lehrnbecher T, Graf N, Hermann J, Niemeyer CM, et al. Less toxicity by optimizing chemotherapy, but not by addition of granulocyte colony-stimulating factor in children and adolescents with acute myeloid leukemia: results of AML-BFM 98. J Clin Oncol. 2006;24:4499-506. (Pubitemid 46646248)
4. Lange BJ, Smith FO, Feusner J, Barnard DR, Dinndorf P, Feig S, et al. Outcomes in CCG-2961, a children's oncology group phase 3 trial for untreated pediatric acute myeloid leukemia: a report from the children's oncology group. Blood. 2008;111:1044-53. (Pubitemid 351213382)
5. Tsukimoto I, Tawa A, Horibe K, Tabuchi K, Kigasawa H, Tsuchida M, et al. Risk-stratified therapy and the intensive use of cytarabine improves the outcome in childhood acute myeloid leukemia: The AML99 trial from the Japanese Childhood AML Cooperative Study Group. J Clin Oncol. 2009;27:4007-13.
6. Rubnitz JE, Inaba H, Dahl G, Ribeiro RC, Bowman WP, Taub J, et al. Minimal residual disease-directed therapy for childhood acute myeloid leukaemia: results of the AML 02 multicentre trial. Lancet Oncol. 2010;11:543-52.
7. Grimwade D, Walker H, Oliver F, Wheatley K, Harrison C, Harrison G, et al. The importance of diagnostic cytogenetics on outcome of AML: analysis of 1612 patients entered into the MRC AML 10 trial. The Medical Research Council Adult and Children's Leukaemia Working Parties. Blood. 1998;92:2322-33. (Pubitemid 28452973)
8. Speck NA, Gilliland DG. Core binding factors in haematopoiesis and leukaemia. Nat Rev Cancer. 2002;2:502-13. (Pubitemid 37328932)
9. Kelly LM, Kutok JL, Williams IR, Boulton CL, Amaral SM, Curley DP, et al. PML/RARalpha and FLT3-ITD induce an APL- like disease in a mouse model. Proc Natl Acad Sci USA. 2002;99:8283-8. (Pubitemid 34651044)
10. Grisolano JL, O'Neal J, Cain J, Tomasson MH. An activated receptor tyrosine kinase, TEL/PDGFbetaR, cooperates with AML1/ETO to induce acute myeloid leukemia in mice. Proc Natl Acad Sci USA. 2003;100:9506-11. (Pubitemid 37033958)
11. Chan IT, Gilliland DG. Oncogenic K-ras in mouse model of myeloproliferative disease and acute myeloid leukemia. Cell Cycle. 2004;3:536-7. (Pubitemid 40278180)
12. Janssen JW, Steenvoorden AC, Collard JG, Nusse R. Oncogene activation in human myeloid leukemia. Cancer Res. 1985;45: 3262-7. (Pubitemid 15007205)
13. Kitayama H, Tsujimura T, Matsumura I, Oritani K, Ikeda H, Ishikawa J, et al. Neoplastic transformation of normal hematopoietic cells by constitutively activating mutations of c-kit receptor tyrosine kinase. Blood. 1996;88:995-1004. (Pubitemid 26333324)
14. Hayakawa F, Towatari M, Kiyoi H, Tanimoto M, Kitamura T, Saito H, et al. Tandem-duplicated Flt3 constitutively activates STAT5 and MAP kinase and introduces autonomous cell growth in IL-3-dependent cell lines. Oncogene. 2000;19:624-31. (Pubitemid 30102913)
15. Bos JL. ras oncogenes in human cancer: a review. Cancer Res. 1989;49:4682-9. (Pubitemid 19213607)
16. Radich JP, Kopecky KJ, Willman CL, Weick J, Head D, Ap- pelbaum F, et al. N-ras mutations in adult de novo acute myelogenous leukemia: prevalence and clinical significance. Blood. 1990;76:801-7. (Pubitemid 20253297)
17. Neubauer A, Dodge RK, George SL, Davey FR, Silver RT, Schiffer CA, et al. Prognostic importance of mutations in the ras proto-oncogenes in de novo acute myeloid leukemia. Blood. 1994;83:1603-11. (Pubitemid 24081575)
18. De Melo MB, Lorand-Metze I, Lima CS, Saad ST, Costa FF. N-RAS gene point mutations in Brazilian acute myelogenous leukemia patients correlate with a poor prognosis. Leuk Lymphoma. 1997;24:309-17. (Pubitemid 27101602)
19. Kiyoi H, Naoe T, Nakano Y, Yokota S, Minami S, Miyawaki S, et al. Prognostic implication of FLT3 and N-RAS gene mutations in acute myeloid leukemia. Blood. 1999;93:3074-80. (Pubitemid 29200800)
20. Meshinchi S, Stirewalt DL, Alonzo TA, Zhang Q, Sweetser DA, Woods WG, et al. Activating mutations of RTK/ras signal transduction pathway in pediatric acute myeloid leukemia. Blood. 2003;102:1474-9. (Pubitemid 36988059)
21. Stirewalt DL, Kopecky KJ, Meshinchi S, Appelbaum FR, Slovak ML, Willman CL, et al. FLT3, RAS, and TP53 mutations in elderly patients with acute myeloid leukemia. Blood. 2001;97:3589-95.
22. Ritter M, Kim TD, Lisske P, Thiede C, Schaich M, Neubauer A. Prognostic significance of N-RAS and K-RAS mutations in 232 patients with acute myeloid leukemia. Haematologica. 2004;89: 1397-9. (Pubitemid 39540581)